Inicio / Oncología / Abstracts de oncología / Neoadjuvant chemotherapy in…

Neoadjuvant chemotherapy in breast cancer: more than just downsizing

0 / 5 (0 votos)
Neoadjuvant chemotherapy in breast cancer: more than just downsizing

The Lancet Oncology

Published:  11 December 2017

DOI: http://dx.doi.org/10.1016/S1470-2045(17)30914-2

Marloes G M Derks, Cornelis J H van de Velde

Background: The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has established a new milestone in evidence-based treatment for early breast cancer. Through longstanding collaboration, mutual trust, and data transparency, they have gathered individual patient data for 4756 women randomly allocated in ten trials to either neoadjuvant chemotherapy (NACT) or adjuvant chemotherapy, with a median follow-up of 9 years (IQR 5–14).

SEGUIR LEYENDO

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.